National Research Co. (NASDAQ:NRCIB) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “National Research Corporation is a leading provider of ongoing survey-based performance measurement, analysis and tracking services to the healthcare industry. The company addresses the growing need of healthcare providers and payers to measure the care outcomes, specifically satisfaction and health status, of their patients and/or members. The company’s primary types of information services are renewable performance tracking services, custom research and a renewable syndicated service. “
Separately, First Analysis cut National Research from an “overweight” rating to an “equal weight” rating and set a $44.00 price objective on the stock. in a research report on Thursday, February 16th.
National Research (NASDAQ:NRCIB) opened at 41.51 on Wednesday. The firm’s 50-day moving average price is $40.30 and its 200-day moving average price is $39.44. The firm has a market cap of $1.01 billion, a P/E ratio of 50.19 and a beta of 0.33. National Research has a 52-week low of $32.18 and a 52-week high of $46.37.
National Research (NASDAQ:NRCIB) last posted its quarterly earnings data on Tuesday, February 14th. The business services provider reported $0.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.01. National Research had a return on equity of 35.36% and a net margin of 18.99%. The business had revenue of $28.37 million for the quarter. Equities research analysts expect that National Research will post $0.92 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 14th. Shareholders of record on Friday, March 31st were given a $0.60 dividend. The ex-dividend date of this dividend was Wednesday, March 29th. This represents a $2.40 annualized dividend and a yield of 5.78%. National Research’s dividend payout ratio is currently 500.00%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rice Hall James & Associates LLC boosted its position in National Research by 1.3% in the third quarter. Rice Hall James & Associates LLC now owns 8,080 shares of the business services provider’s stock valued at $284,000 after buying an additional 105 shares in the last quarter. Isthmus Partners LLC boosted its position in shares of National Research by 2.8% in the third quarter. Isthmus Partners LLC now owns 4,754 shares of the business services provider’s stock worth $165,000 after buying an additional 131 shares in the last quarter. WCM Investment Management CA boosted its position in shares of National Research by 1.2% in the first quarter. WCM Investment Management CA now owns 50,863 shares of the business services provider’s stock worth $1,996,000 after buying an additional 610 shares in the last quarter. Willis Investment Counsel boosted its position in shares of National Research by 6.7% in the fourth quarter. Willis Investment Counsel now owns 29,609 shares of the business services provider’s stock worth $1,234,000 after buying an additional 1,855 shares in the last quarter. Finally, Tudor Investment Corp Et Al purchased a new position in shares of National Research during the fourth quarter worth approximately $213,000. 2.52% of the stock is currently owned by institutional investors and hedge funds.
National Research Co is a business services company in the Health Care Services industry.
Receive News & Ratings for National Research Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Co. and related companies with MarketBeat.com's FREE daily email newsletter.